How to buy Eyenovia stock

Eyenovia, Inc is a biotechnology business based in the US. Eyenovia shares (EYEN) are listed on the NASDAQ and all prices are listed in US Dollars. Eyenovia employs 31 staff and has a trailing 12-month revenue of around 0.00.

Eyenovia share price

Use our graph to track the performance of EYEN stocks over time.

Eyenovia shares at a glance

• Key figures

Information last updated 2021-04-29.

52-week range	$2.55 - $7.72
50-day moving average	$5.60
200-day moving average	$5.20
Wall St. target price	$12.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.97

Buy Eyenovia shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Eyenovia stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Eyenovia, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Eyenovia financials

Revenue TTM	$2 million
Gross profit TTM	$1.2 million
Return on assets TTM	-50.89%
Return on equity TTM	-146.2%
Profit margin	0%
Book value	$0.61
Market capitalisation	$140.9 million

TTM: trailing 12 months

Shorting Eyenovia shares

There are currently 124,591 Eyenovia shares held short by investors – that's known as Eyenovia's "short interest". This figure is 18.9% down from 153,721 last month.

There are a few different ways that this level of interest in shorting Eyenovia shares can be evaluated.

Eyenovia's "short interest ratio" (SIR)

Eyenovia's "short interest ratio" (SIR) is the quantity of Eyenovia shares currently shorted divided by the average quantity of Eyenovia shares traded daily (recently around 102967.76859504). Eyenovia's SIR currently stands at 1.21. In other words for every 100,000 Eyenovia shares traded daily on the market, roughly 1210 shares are currently held short.

However Eyenovia's short interest can also be evaluated against the total number of Eyenovia shares, or, against the total number of tradable Eyenovia shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eyenovia's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Eyenovia shares in existence, roughly 0 shares are currently held short) or 0.0066% of the tradable shares (for every 100,000 tradable Eyenovia shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Eyenovia.

Find out more about how you can short Eyenovia stock.

Eyenovia share dividends

We're not expecting Eyenovia to pay a dividend over the next 12 months.

Eyenovia share price volatility

Over the last 12 months, Eyenovia's shares have ranged in value from as little as $2.55 up to $7.72. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Eyenovia's is 2.1851. This would suggest that Eyenovia's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Eyenovia overview

Eyenovia, Inc. , a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print (MAP) platform technology. The company focuses on to develop clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. Its pipelines focus on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates in pipeline include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc.

Frequently asked questions

• What percentage of Eyenovia is owned by insiders or institutions?

  Currently 36.445% of Eyenovia shares are held by insiders and 7.681% by institutions.

• How many people work for Eyenovia?

  Latest data suggests 31 work at Eyenovia.

• When does the fiscal year end for Eyenovia?

  Eyenovia's fiscal year ends in December.

• Where is Eyenovia based?

  Eyenovia's address is: 295 Madison Avenue, New York, NY, United States, 10017

• What is Eyenovia's ISIN number?

  Eyenovia's international securities identification number is: US30234E1047

• What is Eyenovia's CUSIP number?

  Eyenovia's Committee on Uniform Securities Identification Procedures number is: 30234E104